Brief: Oncternal Therapeutics Presents Updated Interim Data For Zilovertamab In Combination With Ibrutinib At Asco 2022

Oncternal Therapeutics

27/05/2022 24:44

May 26 (Reuters) - Oncternal Therapeutics Inc  ONCT.O :
    * ONCTERNAL THERAPEUTICS PRESENTS UPDATED INTERIM DATA FOR
ZILOVERTAMAB IN COMBINATION WITH IBRUTINIB AT ASCO 2022
    * ONCTERNAL THERAPEUTICS INC - UPDATED MCL AND CLL DATA FROM
CIRLL
STUDY ARE ENCOURAGING AND CONTINUE TO IMPROVE
    * ONCTERNAL THERAPEUTICS INC - DATA FROM P53-MUTATED MCL AND
CLL
PATIENTS SHOW ENCOURAGING RESPONSE RATES IN SUB-GROUP ANALYSES
    * ONCTERNAL - LANDMARK PFS WAS OVER 80% AT 15 MONTHS FOR MCL
&
100% AT 36 MONTHS FOR CLL IN P53-MUTATED PATIENTS TREATED WITH
ZILOVERTAMAB PLUS IBRUTINIB
    * ONCTERNAL THERAPEUTICS INC - COMBINATION OF ZILOVERTAMAB
AND
IBRUTINIB CONTINUED TO BE WELL TOLERATED
    * ONCTERNAL THERAPEUTICS INC - ADVERSE EVENT PROFILE
CONSISTENT OR
IMPROVED COMPARED WITH HISTORICAL DATA FOR IBRUTINIB MONOTHERAPY

Source text for Eikon:  ID:nGNX36Bmp4 
Further company coverage:  ONCT.O 

 ((Reuters.Briefs@thomsonreuters.com;))